Shield Therapeutics Share Discussion Threads

[purchaseatthetop] 27/2/2024 15:10

The problem is that nobody believes a word the BoD say now.

[bolitix] 27/2/2024 15:05

I said a couple of months ago this CEO will take this below 1p share price Even with a 200% sales gain over 2023 he has managed to take the share price down 25 fold to date. VTRS share price is about 13p and i dont know AOPs but which of these who take over we cant expect the share price to ever top theirs. Now i am not gloating here as i have lost lots on STX!

[qipincha] 27/2/2024 15:04

watch their recent presentation again,

Shanbhag did said "we've made adjustments to our business to make sure that our EXISTING RESOURCES get us to cash flow positive in the second half of 25"

also, he highlighted:
*investment directly linked to growth and scaling
*delay or cancel some spend and move them to 2025
*focus on working capital, manage supply chain cost, e.g. API and production cost
*improve distribution process

[qipincha] 27/2/2024 13:56

The other thing I hope is positive, is the new CFO, Santosh Shanbhag, reading his bio, he seems has good reputation in the field. so hope he is good at maths and do not mess around again.


Shield Therapeutics PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Hires Santosh Shanbhag as chief financial officer, effective next Tuesday. He replaces Hans-Peter Rudolf, who left Shield in October to pursue new opportunities. Shanbhag was previously CFO of Nasdaq-listed Akili Inc, which he "helped transform...from a private to a public entity". Before this, he held various senior finance leadership roles at Vertex Pharmaceuticals Inc, including as Head of International Finance & Accounting.


About Vertex

[qipincha] 27/2/2024 13:26

Nope, the company will not finish. But market panic when there is uncertainties. Also, the CEO has not won investors support in recent years.
Saying that, the company still has a good product and currently making approx 4-5m income per quarter and growing. The question is if they have a good saving plan to go through 2024 without asking for further funding. They properly realise it already, hence they mentioned a lot about saving in the recent meeting.
Based on my calculation, if they can keep the cost below 3m per month, they should be able to survive.

[tripletop1] 27/2/2024 13:07

questions, questions, questions..

at a current mcap of <£19m are we really saying the company is finished?

do we really think AOP are going to write-off their c.43% investment they've been holding for years having backed the company on each and every fund raise and extended loans to the comapny to survive in 2022?!

my guess is AOP will protect their investment with another loan to Shield but will demand a reorganistaion, board approval for a takeover etc.

[luckygit] 27/2/2024 12:50

It's well past the time and the sell by date for Board of Directors. They've destroyed share holder value on a mega scale. It's Time for new management or a takeover.

[reviewwworld] 27/2/2024 12:33

Is this actually going to zero. FFS.

[bolitix] 26/2/2024 16:28

I don't understand why someone has not bought this company yet and got rid of this clown CEO. I know there is potential but it needs a stronger CEO at the wheel to realise that potential. Even this doughnut board must be feeling edgy!

[tripletop1] 26/2/2024 15:56

how the volume can just evaporate over the last 2 sessions is beyond understanding..

looking like whoever is left of the small invetsors and traders are done with STX..

don't blame them tbh

only hope value left here.. the hope that AOP take us private or Viatris maybe interested

If it's AOP i would say they wouldn't want to pay much of a premium and if i'm not mistaken can't bid until 12 months after the lapse of the previous (formality) offer (June 2023)

which could leave the door open to Viatris who would have to get any bid to double figures i would imagine before AOP even consider

all conjecture (and mostly wishful thinking on my part)

[lovewinshatelosses] 26/2/2024 11:50

With a lack of inside buys still, and the historic performance here for a long time now, you would have to forgive anyone who came to the conclusion that the BOD are nothing but a bunch of grifters.
IMO, this is shaping up to be a best case scenario DNL-type outcome, which some felt was a stitch up at the time. The lack of fiduciary duty here is absolutely disgusting. I find it really hard to believe that they could have got things so badly wrong for so long, but this is AIM, so likely we will never know. GLA.

[bolitix] 25/2/2024 14:57

When they change name and have 4 products to push through the US market will we be hit with the same 2yr marketing garbage this CEO pushed at take up or do current 100 selling team just sell 4 products with far lower overheads

[weatherman] 23/2/2024 18:20

STX has been manipulated down, some people have made a lot of money by taking advantage of debt weakness - while trusting shareholders have been shafted. STX would have been better off being a private company. Still some of the trouble has been self inflicted - the latest debacle of reporting wrong data, and a slower Q4 with missed targets. Even so, the revenue shortfall wasn't that much with a higher unit price being achieved above forecasts.

[base7] 23/2/2024 15:38

Greg talks a great story but has delivered an almost 100% write down in our share price since he took control.Our share price was recovering nicely at 12/13p until the disastrous 8p raise accompanied by disgraceful & obvious insider trading.AS ever, The Regulator did nothing & those shorting got away with it again.This weeks debacle of over stated prescription targets was another disgrace & either Greg of the CFO should have had an eye or two on that ball-resulting in cashflow break even being pushed back another 6-12 months & Greg & Santosh saying with confidence that we have sufficient cash to achieve that target must be taken with a pinch of salt or our share price would have recovered to the heady heights of 5p.
Greg has been in situ for long enough to sort out Norgine but they continue plodding along doing very little with their rights to sell our products in a market of 500m potential patients - surely we should potentially generate more revenue from Europe than US.
The only near term prospective good news is from Korea & Canada where we should soon be generating revenue - although that too is already several months behind schedule.
The only other action Greg & Santosh could now take to give The Market a sign of their confidence is to invest a relatively small amount of their large packages on a substantial number of share + take some of their remuneration in shares.If I was running a company which I had total belief in I would want as many shares as possible-especially with our share price at a 60%+ discount to the 8p raise .
Rant over - fine weekend to you all !

[bolitix] 23/2/2024 15:23

Changing to Argent Biopharma Ltd - CannEpil (epilepsy/cerebral palsy), CimetrA (acute lung injury/ARDS), CogniCann (Dementia/Alzheimer) are all mature products with a 4yr deal in Holland to sell one of them. I think two are CBD/THC based. Also the two not in the Dutch deal are near end of regularity tests so I think this new strategy is not going to throw us into a general 10 year development window taking drugs from start. I don't think change will happen over night and may be timed with the Dutch deal ending or the fact the Germans are now looking to make cannabis legal.

[bolitix] 23/2/2024 15:17

Yes i have been tough on this CEO and told the company direct what i think (57p down to 2.5!!). I don't however, blame him for the number issue and will soften my view on him but he has no motivation/drive instinct push below him so reported numbers looked out to me and is why i had the a year later in my notes for being cash +tive. they achieved a 200% gain and 100% next year and year after will have them fly and trigger the extra $30m from VTRS (due mainly to $220-240 push). so i just need to accept he will plod along and get there but not at the rate the share price obviously wants. I will cover the name change after this

[chester9] 23/2/2024 14:07

China, Korea, Europe and Canada all given updates. Europe delivered 1.5m which is really poor. The rest are in various stages of getting there but not yet China worst at H2 26

[olosnahjames] 23/2/2024 14:01

Thanks for the feedback.
I know Bolitix has always been very negative on the CEO. I never agreed with him, after all this was the new management and surely better than the original. But no, I have to agree with him now. Truly shocking with the sales figures error.
But surely there must be underperforming sales reps, and how is this dealt with if they are Viatrus staff?
Also, no mention of Canada or China? They mentioned they were due a meeting with the China partner during a previous presentation, but that was many months ago. Surely they would have been keen to give away any positives after such a bad update. I haven’t listened to the presentation yet, just can’t bring myself to, literally no faith in what they say.

[chester9] 23/2/2024 13:47

hTTps://podcasts.apple.com/gb/podcast/the-sharepickers-podcast-with-justin-waite/id910474791Vadim Alexandre and Justin Waite pick apart Shield. They conclude they would not buy in on the drop as too much is unknown about covenants, cash shortfall. It's actually very good discussion with Vadim who has been following Shield for 7 years but has never bought in. He states he may buy in if cash to profitability is sorted by another raise.

[wallywoo] 23/2/2024 10:16

Stay well clear. "Ask yourself the question. Why is a tiny microcap with a awful track record always on the top popular 10 BB'S on advfn??"Answer; because it issues shares like sweets and is peddled by every boiler room outfit and conmen. Stay well clear

[qipincha] 23/2/2024 09:17

I have managed to attend the meeting and added some tough questions, including reducing salary/remuneration, instead pay share

I also did some calculation.

Assuming they can maintain the 20% quarterly growth rate (which is the lower end using 2023 data), with current averaged price of $145 (could be better), and $3.3m monthly spend, they can managed through, without asking for further funding.

hxxps://www.insidermedia.com/news/north-east/shield-therapeutics-secures-20m-debt-facility-amid-excellent-period

In fact, I am not sure what the concern is if there is a $20m debt facility available. Unless they have already drawn down from it.

The key elements to the following years are growth rate, unit sale price and saving on cost.

Also, there may be extra income from Viatris and other collaborators. Does anyone know the detail of the milestone payment? STX received a milestone payment in 2023 (around $4.4m), and they can receive up to $30m.

Ex-US sales could also add $2m in 2024 in the balance based on H2 2023 number.